REGISTERED NUMBER: 10455021 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 1 NOVEMBER 2016 TO 30 NOVEMBER 2017

FOR

MED-PHARM HOLDINGS LIMITED

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 NOVEMBER 2016 TO 30 NOVEMBER 2017

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

MED-PHARM HOLDINGS LIMITED

COMPANY INFORMATION
FOR THE PERIOD 1 NOVEMBER 2016 TO 30 NOVEMBER 2017

DIRECTOR:	Z Z Musaji
REGISTERED OFFICE:	2 Mill Road Haverhill Suffolk CB9 8BD
REGISTERED NUMBER:	10455021 (England and Wales)
ACCOUNTANTS:	Hackett Griffey LLP Chartered Certified Accountants 2 Mill Road Haverhill Suffolk CB9 8BD

BALANCE SHEET
30 NOVEMBER 2017

	Notes	£	£
FIXED ASSETS			
Investments	3		74,250
CURRENT ASSETS			
Cash at bank		750	
CREDITORS			
Amounts falling due within one year	4	75,603	
NET CURRENT LIABILITIES			(74,853)
TOTAL ASSETS LESS CURRENT LIABILITIES			(603)
CAPITAL AND RESERVES			
Called up share capital			100
Retained earnings			(703)
			(603)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 November 2017.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 November 2017 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 18 July 2018 and were signed by:

Z Z Musaji - Director

The notes form part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 NOVEMBER 2016 TO 30 NOVEMBER 2017

1. STATUTORY INFORMATION

Med-Pharm Holdings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. FIXED ASSET INVESTMENTS

	Interest in other participating interests £
COST	
Additions	74,250
At 30 November 2017	74,250
NET BOOK VALUE	
At 30 November 2017	74,250

4. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	£
Other creditors	75,603

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.